Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

V.B.C. Biemans*, F. Hoentjen, M.J. Pierik

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)92-92
Number of pages1
JournalNew England Journal of Medicine
Issue number1
Publication statusPublished - 2 Jan 2020

Cite this